Drugs With Semaglutide Linked to Deep Vein Thrombosis and Pulmonary Embolism
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient. Semaglutide is associated with a significantly increased risk of blood clots. Ozempic, Wegovy, and Rybelsus causing deep vein thrombosis (DVT) and pulmonary embolism (PE) as blood clots side effects is a drug safety issue that is not well-known. Rather, blood clots have been overshadowed by gastrointestinal and stomach problems linked to Ozempic, Wegovy, and Rybelsus, such as gastroparesis.
We are looking into possible drug injury lawsuits for patients who developed deep vein thrombosis (DVT) or pulmonary embolism (PE) due to these severe blood clots side effects of semaglutide weight-loss drugs Ozempic, Wegovy, and Rybelsus.
No Warnings About Blood Clots Side Effects
There are no warnings about an increased risk of blood clots side effects in the current drug labels for Ozempic, Wegovy, and Rybelsus. This failure to warn by Novo Nordisk (the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus) is a drug safety issue for two reasons:
- A 2021 medical journal article reported that researchers found semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, increased the risk of deep vein thrombosis (DVT) by 266% in patients with type 2 diabetes.
- The blood clots side effects for Ozempic, Wegovy, and Rybelsus are particularly alarming since patients with type 2 diabetes who are also overweight already have an increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Those two reasons become more clear when taking into consideration this background information about semaglutide weight-loss drugs:
- The FDA approved Ozempic as a Type 2 diabetes treatment, such that Ozempic is being used “off-label” for weight loss;
- Likewise, Rybelsus was approved as Type 2 diabetes treatment so it, too, is being used “off-label” for weight loss; and,
- Only Wegovy was approved by the FDA as a treatment for adult obesity and “indicated” for weight loss, so it is not being used “off-label” for weight loss.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients hospitalized with deep vein thrombosis (DVT) or pulmonary embolism (PE) would be filed against Novo Nordisk for this failure to warn about the blood clots side effects of semaglutide. Those legal cases would not be filed against the patient’s doctor because there were no warnings about an increased risk of blood clots for Ozempic, Wegovy, and Rybelsus.
Free Case Evaluation for Blood Clots Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit a Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his more than 20 years of experience handling drug injury cases.
Most Recent Article About Ozempic, Wegovy, and Rybelsus
Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
Adverse event reports that involve severe stomach conditions such as gastroparesis, gastric stasis, and stomach paralysis associated with Ozempic, Wegovy, and Rybelsus, the three popular GLP-1 receptor agonists containing semaglutide used as weight-loss drugs, are relatively well-known by now. In comparison, Wegovy, Rybelsus, and Ozempic deep vein thrombosis side effects have not received much attention.
Remarkably, medical researchers found that semaglutide — and therefore Wegovy, Rybelsus, and Ozempic — increased the risk of deep vein thrombosis (DVT) by 266% in patients with type 2 diabetes. The medical journal article that reported this semaglutide DVT side effect finding is “Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials”, published by the Endocrine Journal back in 2021.
Wegovy, Rybelsus, and Ozempic deep vein thrombosis side effects are particularly alarming since patients who have type 2 diabetes and who are obese are already at an increased risk of DVT. Significantly, the authors of this 2021 Endocrine Journal article suggested that Ozempic, Rybelsus, and Wegovy perhaps should be avoided by obese people with type 2 diabetes patients due to this semaglutide DVT side effect finding.
Here is some medical information about deep vein thrombosis (also known as deep venous thrombosis) from the Mayo Clinic, the U.S. National Institute of Health’s Medline Plus, and the Centers for Disease Control and Prevention.
We are investigating possible drug injury lawsuits involving Wegovy, Rybelsus, and Ozempic deep vein thrombosis side effects.
[Read article in full at original source]Earlier articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages